Finally, because of the high expression of AR in CTCs from TNBC patients, we explored the effect of pharmacological inhibition of the AR pathway, which is a common therapeutic strategy in AR-dependent tumors such as prostate cancer [21]. This evidence concerns the gene AR and Familial prostate cancer.